Breaking News Instant updates and real-time market news.

LGND

Ligand

$118.65

-0.59 (-0.49%)

, AMGN

Amgen

$177.13

2.09 (1.19%)

09:05
07/17/17
07/17
09:05
07/17/17
09:05

Ligand enters into commercial license and supply agreement with Amgen

Ligand (LGND) announced that it has entered into a commercial license and supply agreement with Amgen (AMGN), granting rights to use Ligand's Captisol technology in the formulation of AMG 330. Captisol is a patent protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. AMG 330 is an anti-CD33 x anti-CD3 bispecific antibody construct. It is being investigated as a treatment for acute myeloid leukemia by Amgen.This license agreement replaces the prior research agreement which allowed Amgen to evaluate AMG 330 with Captisol in preclinical and early clinical studies. Under this new commercial license agreement, Amgen receives exclusive worldwide rights to combine Captisol with AMG 330 for use in humans for a wide variety of therapeutic indications. In addition to an upfront payment, Ligand is entitled to potential milestone payments, royalties and revenue from future sales of AMG 330 formulated using Captisol.

LGND

Ligand

$118.65

-0.59 (-0.49%)

AMGN

Amgen

$177.13

2.09 (1.19%)

  • 17

    Jul

  • 19

    Jul

  • 19

    Jul

  • 25

    Jul

  • 14

    Aug

  • 14

    Sep

  • 03

    Feb

LGND Ligand
$118.65

-0.59 (-0.49%)

02/27/17
ROTH
02/27/17
INITIATION
Target $118
ROTH
Buy
Ligand reinitiated with a Buy at Roth Capital
Roth Capital analyst Scott Henry resumed coverage of Ligand Pharmaceuticals with a Buy rating and $118 price target, citing the combination of a "strong" base business, near-term new revenue generators, and a long-term pipeline.
02/15/17
SPHN
02/15/17
NO CHANGE
Target $125
SPHN
Overweight
Ending of Merck trial neutral to Ligand, says Stephens
Stephens analyst Drew Jones says that there could be some initial weakness in Ligand's (LGND) shares due to the negative headline associated with Merck (MRK) stopping one of the trials for its BACE inhibitor, but expects this to be short lived. The analyst says the success with Merck's BACE inhibitor is not a part of his positive thesis as he continue to see multiple potential commercial, clinical, and regulatory catalysts for Ligand throughout 2017. He reiterates an Overweight rating and $125 price target on Ligand's shares.
11/07/16
SPHN
11/07/16
NO CHANGE
Target $125
SPHN
Overweight
Ligand price target lowered to $125 from $150 at Stephens
Stephens analyst Drew Jones lowered his price target for Ligand to $125 from $150 on valuation. The analyst notes that the company reported mixed Q3 results as revenue softness led to lowered guidance for the year. Nonetheless, he reiterates an Overweight rating on the shares.
10/10/16
ROTH
10/10/16
NO CHANGE
Target $154
ROTH
Buy
Ligand price target raised to $154 after Carnexiv approval at Roth Capital
Roth Capital analyst Joseph Pantginis raised his price target on Ligand to $154 from $150 after partner Lundbeck announced that the FDA approved Carnexiv injection as a short-term replacement therapy for oral carbamazepine formulations in adults with certain seizure types. Ligand will receive a $1.25M milestone payment this quarter and is entitled to receive a 2.75% royalty on sales of the drug, noted Pantginis, who keeps a Buy rating on Ligand shares.
AMGN Amgen
$177.13

2.09 (1.19%)

07/17/17
JEFF
07/17/17
NO CHANGE
Target $195
JEFF
Buy
Amgen Complete Response Letter was expected, says Jefferies
Jefferies analyst Michael Yee says the FDA's Complete Response Letter for Amgen's Romosozumab in osteoporosis was expected. The indication is not in current consensus near-term estimates given the prior known imbalance in safety signal, Yee tells investors in a research note. He believes the drug could still be approved in 2018-2019 based on a good risk/benefit profile. The analyst has a Buy rating on Amgen with a $195 price target.
06/23/17
06/23/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Starbucks (SBUX) initiated with an Overweight at KeyBanc. 2. Wix.com (WIX) initiated with an Outperform at Wedbush. 3. Red Hat (RHT) initiated with a Neutral at Piper Jaffray. 4. Amgen (AMGN) initiated with a Hold at Deutsche Bank. 5. Oclaro (OCLR) initiated with a Buy at DA Davidson. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/23/17
DBAB
06/23/17
INITIATION
Target $172
DBAB
Hold
Amgen initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Andrew Peters started Amgen with a Hold rating and $172 price target, saying its valuation is largely in line with its near-term growth challenges.
06/22/17
LEER
06/22/17
NO CHANGE
LEER
Leerink sees reasons for biotech rally to continue
Leerink analyst Geoffrey Porges attributes the recent strength in the biotech sector to a lessening of the perceived fears of pricing regulations and a favorable tone from the FDA. However, he believes the sector could advance at least 15% more, as he foresees more positive operating results and still expects more industry consolidation. Among large cap biotech names, Porges maintains Outperform ratings on Regeneron (REGN), Celgene (CELG), Vertex (VRTX) and Alexion(ALXN) and keeps Market Perform ratings on AbbVie (ABBV), Amgen (AMGN), Gilead (GILD) and Biogen (BIIB).

TODAY'S FREE FLY STORIES

TGT

Target

$60.08

0.05 (0.08%)

10:42
10/19/17
10/19
10:42
10/19/17
10:42
Hot Stocks
Target says small-format store in Herald Square to open October 20 »

Target tweeted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

UAL

United Continental

$63.93

-4.06 (-5.97%)

10:40
10/19/17
10/19
10:40
10/19/17
10:40
Hot Stocks
United Continental says Q3 involuntary denied boardings down 92% y/y »

Says employees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

VRX

Valeant

$12.10

-0.29 (-2.34%)

10:40
10/19/17
10/19
10:40
10/19/17
10:40
Options
Higher options volume in Valeant as one player banks a big profit »

Higher options volume in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

BP

BP

$38.81

0.09 (0.23%)

10:36
10/19/17
10/19
10:36
10/19/17
10:36
Hot Stocks
BP chairman Carl-Henric Svanberg announces intention to retire »

BP announces that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MON

Monsanto

$121.99

-0.09 (-0.07%)

, AGCO

Agco

$70.84

-0.91 (-1.27%)

10:33
10/19/17
10/19
10:33
10/19/17
10:33
Hot Stocks
Monsanto's Climate Corp announces data connectivity agreement with Agco »

The Climate Corporation,…

MON

Monsanto

$121.99

-0.09 (-0.07%)

AGCO

Agco

$70.84

-0.91 (-1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

FCEL

FuelCell

$2.13

0.09 (4.41%)

10:31
10/19/17
10/19
10:31
10/19/17
10:31
Hot Stocks
FuelCell to supply power to Navy base in Connecticut »

FuelCell Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

10:30
10/19/17
10/19
10:30
10/19/17
10:30
General news
EIA natural gas storage change for week ending October 13 »

Gas inventories 51 Bcf…

MU

Micron

$41.65

1.26 (3.12%)

10:30
10/19/17
10/19
10:30
10/19/17
10:30
Options
Active trading in Micron calls as shares slump Thursday »

Active trading in Micron…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 23

    Oct

NKE

Nike

$52.21

-0.0915 (-0.17%)

, ADDYY

adidas

$112.54

-0.08 (-0.07%)

10:29
10/19/17
10/19
10:29
10/19/17
10:29
Hot Stocks
Goldman Sachs cuts Nike rating ahead of investor day on excess inventory »

This morning, Goldman…

NKE

Nike

$52.21

-0.0915 (-0.17%)

ADDYY

adidas

$112.54

-0.08 (-0.07%)

GRPN

Groupon

$5.00

0.05 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 01

    Nov

  • 16

    Nov

ULTA

Ulta Beauty

$200.90

2.59 (1.31%)

10:29
10/19/17
10/19
10:29
10/19/17
10:29
Rumors
Rumor moving shares of Ulta Beauty »

Rumor: Ulta Beauty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:25
10/19/17
10/19
10:25
10/19/17
10:25
General news
Today's U.S. reports »

Today's U.S. reports…

UAL

United Continental

$64.26

-3.73 (-5.49%)

10:23
10/19/17
10/19
10:23
10/19/17
10:23
Technical Analysis
Technical View: United Continental falls after results and outlook »

The company reported Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

MEIP

MEI Pharma

$2.48

0.15 (6.44%)

10:23
10/19/17
10/19
10:23
10/19/17
10:23
Hot Stocks
MEI Pharma's pracinostat granted EU orphan designation »

Pracinostat was granted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$50.08

1.431 (2.94%)

10:20
10/19/17
10/19
10:20
10/19/17
10:20
Options
Notable ratio spread in Verizon as shares rally on earnings »

Notable ratio spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 01

    Nov

10:20
10/19/17
10/19
10:20
10/19/17
10:20
General news
Treasury Action: yields resumed their slide »

Treasury Action: yields…

$NSD

NASDAQ Market Internals

10:17
10/19/17
10/19
10:17
10/19/17
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

10:16
10/19/17
10/19
10:16
10/19/17
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$63.76

0.25 (0.39%)

, TEVA

Teva

$14.61

-0.01 (-0.07%)

10:15
10/19/17
10/19
10:15
10/19/17
10:15
Periodicals
Merck wins appeal to revive NuvaRing patent case against Teva, Bloomberg says »

An appeals court said a…

MRK

Merck

$63.76

0.25 (0.39%)

TEVA

Teva

$14.61

-0.01 (-0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 23

    Oct

  • 27

    Oct

  • 02

    Nov

  • 06

    Nov

  • 08

    Nov

  • 16

    Nov

  • 30

    Nov

  • 02

    Feb

ADP

ADP

$113.93

0.21 (0.18%)

10:15
10/19/17
10/19
10:15
10/19/17
10:15
Hot Stocks
Pershing Square releases additional questions for ADP »

Pershing Square Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 02

    Nov

10:15
10/19/17
10/19
10:15
10/19/17
10:15
General news
U.S. leading economic index fell 0.2% to 128.6 in September »

U.S. leading economic…

10:15
10/19/17
10/19
10:15
10/19/17
10:15
General news
Breaking General news story  »

Week of 10/13 EIA Natural…

GS

Goldman Sachs

$240.07

-1.96 (-0.81%)

10:13
10/19/17
10/19
10:13
10/19/17
10:13
Hot Stocks
Blankfein: 'Just left Frankfurt,' 'I'll be spending a lot more time there' »

Goldman Sachs Chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

EVHC

Envision Healthcare

$40.70

0.05 (0.12%)

10:11
10/19/17
10/19
10:11
10/19/17
10:11
Periodicals
Starboard's Smith to pitch Envision Healthcare as long idea, Bloomberg says »

Starboard Value's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

NNI

Nelnet

$51.05

-0.27 (-0.53%)

10:10
10/19/17
10/19
10:10
10/19/17
10:10
Upgrade
Nelnet rating change  »

Follow-up: Nelnet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$12.30

0.4 (3.36%)

10:10
10/19/17
10/19
10:10
10/19/17
10:10
Options
Short-term call buyer in Ceaser's opens a notable new position »

Short-term call buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.